Payment overview · 2025
General Payments
$396.94
22 reported records · 11 companies
Healthcare provider profile · identity verified
Daniel M Metzger, MD
Allopathic & Osteopathic Physicians|Family Medicine · NILES, MI · NPI 1265478192
Verified facts
What the public records show
CMS Open Payments records show Daniel M Metzger, MD received $396.94 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $117.81 | 29.7% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $93.83 | 23.6% | 5 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.93 | 9.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.65 | 7.7% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $20.90 | 5.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.32 | 4.9% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.46 | 4.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.55 | 3.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.48 | 3.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.17 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.84 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $396.94 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.74 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.06 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 331 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 264 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 46 |
| Metformin Hcl | Metformin Hcl | 199 | 48 |
| Losartan Potassium | Losartan Potassium | 174 | 41 |
| Lisinopril | Lisinopril | 163 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 27 |
| Omeprazole | Omeprazole | 124 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 33 |
| Gabapentin | Gabapentin | 95 | 21 |
| Farxiga | Dapagliflozin Propanediol | 89 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 17 |
| Sertraline Hcl | Sertraline Hcl | 85 | 21 |
| Simvastatin | Simvastatin | 84 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 29 |
| Famotidine | Famotidine | 74 | 18 |
| Chlorthalidone | Chlorthalidone | 73 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 16 |
| Indapamide | Indapamide | 72 | 14 |
| Spironolactone | Spironolactone | 71 | 20 |
| Tramadol Hcl | Tramadol Hcl | 70 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 23 |
| Allopurinol | Allopurinol | 61 | 16 |
| Pregabalin | Pregabalin | 60 | suppressed |
| Lovastatin | Lovastatin | 59 | 16 |
| Buspirone Hcl | Buspirone Hcl | 58 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 11 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Glimepiride | Glimepiride | 49 | 13 |
| Carvedilol | Carvedilol | 48 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | suppressed |
| Eliquis | Apixaban | 47 | suppressed |
| Meloxicam | Meloxicam | 46 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 15 |
| Trazodone Hcl | Trazodone Hcl | 41 | suppressed |
| Jardiance | Empagliflozin | 38 | 13 |
| Furosemide | Furosemide | 37 | 11 |
| Ondansetron Odt | Ondansetron | 37 | 12 |
| Finasteride | Finasteride | 36 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Prednisone | Prednisone | 34 | 21 |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 15 |
| Linzess | Linaclotide | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Valsartan | Valsartan | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $396.94 · 22 records | ABBVIE INC. | Azstarys, Dexcom G6 Transmitter, EVENITY, JARDIANCE, Jornay PM, Kerendia, QULIPTA, Qelbree, REXULTI, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error